Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of iGlarLixi on Brain Insulin Sensitivity in T2D
NCT03881995Phase 4Terminated
- Sponsor
- University Hospital Tübingen
- Start
- Mar 2019
- Primary completion
- Jun 2020
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 4 trial of lixisenatide in type 2 diabetes mellitus (T2DM), sponsored by University Hospital Tübingen. Started Mar 2019; status: terminated.
02
Drugs
lixisenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03881995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03881995.